This discovery led to the development of therapeutics to target these precise mutations such as trastuzumab (Herceptin), which is the first approved precision therapeutic to combat breast cancer caused by overexpression of the HER2 gene136,138,139. This evidence concerns the gene ERBB2 and breast carcinoma.